“We have found Limbus Contour’s AI-driven solution to be a technology leader in speed, accuracy and versatility. Depending on the complexity of the treatment plan, we expect contouring time reductions of up to 80%1, thus ensuring that patients receive timely treatment.” Sam Mazin, Ph.D., Co-founder and Chief Technology Officer at RefleXion. https://bit.ly/49n8oR2
RefleXion Medical
Medical Equipment Manufacturing
Hayward, CA 13,645 followers
SCINTIX biology-guided radiotherapy is now FDA cleared.
About us
SCINTIX biology-guided radiotherapy now FDA cleared. SCINTIX® therapy detects and responds to signals emitted from the cancer itself and, for the first time, uses them to deliver immediate treatment for tumors in the lung or bone that may arise from primary or metastatic disease.
- Website
-
http://www.reflexion.com
External link for RefleXion Medical
- Industry
- Medical Equipment Manufacturing
- Company size
- 201-500 employees
- Headquarters
- Hayward, CA
- Type
- Privately Held
- Founded
- 2009
- Specialties
- cancer care, radiation therapy, life sciences, medical devices, biotechnology, oncology, manufacturing, PET scanner, electrical engineering, product engineering, algorithms engineer, new product development, and software engineering
Locations
-
Primary
25841 Industrial Blvd
Suite 275
Hayward, CA 94545, US
Employees at RefleXion Medical
Updates
-
The better the underlying images, the better algorithms like deformable registration or AI-based auto-contouring will inherently perform. Ottar Schmitz, Senior Director of External Innovation, digs into some of the advantages the high-quality, 16-slice kVCT fan-beam imaging on the RefleXion X1 platforms brings to radiotherapy.
-
Don't miss the latest episode of the Accelerators Podcast! RefleXion's Samuel Mazin, Phd, Founder and CTO, and Sean Shirvani, MD MPH, Chief Medical Officer, sit down with hosts Matt Spraker, MD and Simul Parikh, MD to talk all things RefleXion and SCINTIX biology-guided radiotherapy. https://lnkd.in/gvRx-Zri
“Cambrian Explosion of Radiotracers”: In Conversation With Sam and Sean From RefleXion - The Accelerators Podcast
buzzsprout.com
-
SCINTIX therapy is a new modality in radiotherapy. Following an injection with the radiotracer, fludeoxyglucose (FDG-18), tumors continuously generate signals detected by our X1 platform, to determine where radiation should be delivered. Learn more about this new option for patients at scintixtherapy.com
-
-
At RefleXion, we understand the relentless spirit of champions—because we're relentless in working to beat cancer. 💪 #RefleXion #ChampionSpirit #FightCancer #CancerTreatment
-
-
Advances in imaging technology offer a bright future for radiation therapy, with the possibility of someday performing inter-fraction analysis of the tumor’s response at a radiomic level. Explore how RefleXion is pursuing this future with Ottar Schmitz, Senior Director of External Innovation. #innovation #cancercare #radiotherapy
-
RefleXion Medical reposted this
Arnold Pompos, Ph.D., Associate Professor and Associate Vice Chair, Strategic Initiatives and Capital Investments, gave an invited talk yesterday at the RefleXion luncheon during the #aapm2024 meeting. His talk was titled, "Case study of multitargeted delivery: SCINTIX combined with X-ray guided SBRT." #medphys #physics #physicist #radiationoncology #cancercare #utsw
-
-
Great turnout today for our luncheon at AAPM 2024! Thank you to everyone who showed up to learn more about SCINTIX multi-target treatment and to our presenters Murat Surucu, Ph.D. (Stanford University), Arnold Pompos, Ph.D. (University of Texas Southwestern), Tyler Watkins, Ph.D. (City of Hope), and David Carlson, Ph.D. (Yale New Haven Health).
-
Happening now at #AAPM2024. Join us in meeting room 515A to hear from colleagues as they share their latest clinical experience with SCINTIX biology-guided radiotherapy.
-
-
Join us today at 12:30 PM to hear colleagues share their latest clinical experience with SCINTIX® therapy. Presenters include Murat Surucu, Ph.D. (Stanford University), Arnold Pompos, Ph.D. (University of Texas Southwestern), Tyler Watkins, Ph.D. (City of Hope), and David Carlson, Ph.D. (Yale New Haven Health).
-